Adalimumab levels detected in cord blood and infants exposed in utero
Researchers detected adalimumab levels in cord blood and infants exposed to the medication in utero, highlighting the need for close monitoring of infection risk in newborns. The study suggests that pregnant women with Crohn's disease should not discontinue the medication, as it may exacerbate flares and lead to complications.